IL310115A - Treatment of his hyporesponders - Google Patents
Treatment of his hyporespondersInfo
- Publication number
- IL310115A IL310115A IL310115A IL31011524A IL310115A IL 310115 A IL310115 A IL 310115A IL 310115 A IL310115 A IL 310115A IL 31011524 A IL31011524 A IL 31011524A IL 310115 A IL310115 A IL 310115A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- use according
- obicetrapib
- therapy
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187721 | 2021-07-26 | ||
| PCT/EP2022/070780 WO2023006657A1 (en) | 2021-07-26 | 2022-07-25 | Treatment of his hyporesponders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310115A true IL310115A (en) | 2024-03-01 |
Family
ID=77358089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310115A IL310115A (en) | 2021-07-26 | 2022-07-25 | Treatment of his hyporesponders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230041138A1 (https=) |
| EP (1) | EP4376832B1 (https=) |
| JP (1) | JP2024527023A (https=) |
| KR (1) | KR20240040767A (https=) |
| CN (1) | CN117940125A (https=) |
| AU (1) | AU2022320869A1 (https=) |
| CA (1) | CA3227153A1 (https=) |
| IL (1) | IL310115A (https=) |
| MX (1) | MX2024001170A (https=) |
| WO (1) | WO2023006657A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2025146415A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| WO2026062050A1 (en) * | 2024-09-17 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
| ES2926775T3 (es) | 2014-08-12 | 2022-10-28 | Newamsterdam Pharma B V | Proceso de preparación de intermedios sintéticos para la preparación de derivados de tetrahidroquinolina |
| CA2959488C (en) | 2014-08-28 | 2023-06-20 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors |
-
2022
- 2022-07-25 MX MX2024001170A patent/MX2024001170A/es unknown
- 2022-07-25 CA CA3227153A patent/CA3227153A1/en active Pending
- 2022-07-25 WO PCT/EP2022/070780 patent/WO2023006657A1/en not_active Ceased
- 2022-07-25 AU AU2022320869A patent/AU2022320869A1/en active Pending
- 2022-07-25 EP EP22754412.9A patent/EP4376832B1/en active Active
- 2022-07-25 CN CN202280057367.XA patent/CN117940125A/zh active Pending
- 2022-07-25 JP JP2024504808A patent/JP2024527023A/ja active Pending
- 2022-07-25 IL IL310115A patent/IL310115A/en unknown
- 2022-07-25 KR KR1020247005859A patent/KR20240040767A/ko active Pending
- 2022-07-25 US US17/873,009 patent/US20230041138A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202310842A (zh) | 2023-03-16 |
| US20230041138A1 (en) | 2023-02-09 |
| KR20240040767A (ko) | 2024-03-28 |
| CA3227153A1 (en) | 2023-02-02 |
| MX2024001170A (es) | 2024-05-14 |
| AU2022320869A1 (en) | 2024-02-01 |
| WO2023006657A1 (en) | 2023-02-02 |
| JP2024527023A (ja) | 2024-07-19 |
| EP4376832B1 (en) | 2026-03-25 |
| EP4376832A1 (en) | 2024-06-05 |
| CN117940125A (zh) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310115A (en) | Treatment of his hyporesponders | |
| FI3448426T3 (fi) | Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon | |
| Sisk et al. | Comparison of preoperative and postoperative diflunisal for suppression of postoperative pain | |
| US20120202849A1 (en) | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease | |
| CN1440283A (zh) | 有机化合物的联合形式 | |
| IL300151A (en) | Combinations for cancer treatment | |
| CA2382387A1 (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
| JP2024507810A5 (https=) | ||
| JP2002523370A5 (https=) | ||
| JP2024527023A5 (https=) | ||
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| CN104244935A (zh) | 用于联合治疗的药物组合物 | |
| JP2023538522A5 (https=) | ||
| US8399518B2 (en) | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| GR990100388A (el) | Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος.... | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP2004525143A5 (https=) | ||
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| JP2010505866A5 (https=) | ||
| JP7109093B2 (ja) | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 | |
| JP2023526418A5 (https=) | ||
| WO2009100245A1 (en) | Low dose hmg-coa reductase inhibitor with reduced side effects | |
| Garnett | A review of current clinical findings with fluvastatin | |
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance |